News about phase 1 trial for mCRPC: BMS-986365

[Maxone73]

Plenty of hopefully good news at ASCO 2024 on the 25th of Jan

"First disclosure of clinical outcomes from Phase 1 trial with BMS-986365 (CC-94676), the company’s first androgen receptor ligand-directed degrader in solid tumors from its targeted protein degradation platform, in metastatic castration-resistant prostate cancer"

biospace.com/article/releas...

[KocoPr]

Very interesting. Looking forward to seeing the results and get going on a phase2 trial asap

“First presentation of clinical outcomes from the company’s targeted protein degradation platform in solid tumors with Phase 1 data from BMS-986365 (CC-94676), an oral drug selectively targeting AR. BMS-986365 induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors (ARPI) therapies and shows promising clinical activity in heavily pre-treated patients with mCRPC across wildtype, amplified and mutant AR status, highlighting this asset as the potential best-in-class AR-ligand directed degrader that may help overcome resistance to standard of care ARPIs in patients with mCRPC, a difficult-to-treat tumor type.”

[KocoPr in reply to KocoPr]

the presentation schedule is jan 25th and abstracts available on the 22nd

news.bms.com/news/details/2...

All abstracts except late-breaking abstracts will be available on ASCO’s digital program at 5:00 PM Eastern Time (ET) on January 22, 2024. All late-breaking abstracts will be available on ASCO’s digital program at 10:00 AM ET on their day of presentation at the meeting.

[Maxone73 in reply to KocoPr]

Good catch!!